January 1, 2003
Overview of the Glycoprotein IIb/IIIa Interventional Trials
Population
Patients undergoing percutaneous coronary revascularization
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Offers mechanistic support for GP IIb/IIIa inhibitors in PCI; leaves open optimal integration with contemporary regimens.
Structured PICO
P
Population
Patients undergoing percutaneous coronary revascularization
I
Intervention
Glycoprotein (GP) IIb/IIIa receptor inhibitors
Glycoprotein IIb/IIIa inhibitors potently inhibit platelet aggregation by blocking the final common pathway, offering a strategy to prevent ischemic complications during percutaneous coronary revascularization.
Cite This Study
Lincoff et al. (2003) studied this question.